Healthcare, Pharma & Life Sciences

Gan & Lee Licenses Obesity Drug to Menarini in Deal Worth Up to €726M

Image
Gan & Lee Licenses Obesity Drug to Menarini in Deal Worth Up to €726M

Beijing/Florence – September 09, 2026 -- Gan & Lee Pharmaceuticals (603087.SH) has signed an exclusive licensing agreement with Italy's The Menarini Group for its GLP-1 receptor agonist bofanglutide, a deal worth up to €726 million excluding royalties.

Gan & Lee secures €62 million upfront payment plus milestone potential of €664 million

Under the terms, Gan & Lee will receive a €62 million upfront payment, up to €664 million in milestone payments, and double-digit royalties on net sales across the licensed territory. Menarini will handle regulatory filings and commercialization in 39 countries, covering all 27 European Union member states, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkan nations.

Thryv Licenses Second SGK1 Scaffold, Eyes Parkinson's and Alzheimer's

Image
Thryv Licenses Second SGK1 Scaffold, Eyes Parkinson's and Alzheimer's

San Francisco – September 09, 2026 -- Thryv Therapeutics Inc. has signed an exclusive, worldwide, royalty-bearing license for a new SGK1 inhibitor chemical series, opening a path toward Parkinson's and Alzheimer's disease treatments alongside its existing cardiac drug programs. The agreement with Spain's Consejo Superior de Investigaciones Científicas (CSIC), the Autonomous University of Madrid (UAM) and Fundación de la Universidad Autónoma de Madrid (FUAM) became effective September 09, 2026, granting Thryv rights across all fields of use and territories, with sublicensing rights included.

ECRI Adds Aviation, Nuclear Safety Expert Meshkati to Board

Image
ECRI Adds Aviation, Nuclear Safety Expert Meshkati to Board

Fort Washington, Pa. – September 09, 2026 -- ECRI, a global authority on healthcare safety and quality, has appointed Professor Najmedin Meshkati, PhD, to its Board of Trustees, bringing nearly four decades of complex-systems safety research from aviation, nuclear power, and petrochemical operations to the nonprofit's patient safety mission.

Meshkati investigated the world's most scrutinized industrial disasters

Professor Meshkati has examined the BP Texas City Refinery explosion, the Deepwater Horizon oil spill, and the Fukushima Daiichi nuclear disaster. He testified before the U.S. Senate Committee on Commerce, Science, and Transportation as a member of the FAA's independent Expert Panel on Boeing, which reviewed the company's safety management system and safety culture. He currently chairs the State of California's Diablo Canyon Independent Safety Committee.

Pulnovo's PADN Cuts Clinical Worsening Risk 51% in NEJM-Published Trial

Shanghai – September 09, 2026 -- Pulnovo Medical's pulmonary artery denervation (PADN) system reduced the risk of clinical worsening by 51% in patients with pulmonary hypertension linked to left heart disease (PH-LHD), according to results from the PADN-HF-PH trial presented at the European Society of Cardiology (ESC) Congress 2026 and simultaneously published in The New England Journal of Medicine.

Trial enrolled 264 patients across multiple centers under academician Yaling Han

The multicenter, randomized controlled study, led by academician Yaling Han of the General Hospital of Northern Theater Command, evaluated PADN as an add-on to guideline-directed medical therapy (GDMT) versus GDMT alone. Corresponding authors on the NEJM paper include Professor Shao-Liang Chen of Nanjing First Hospital and Professor Gregg W. Stone of Mount Sinai Hospital.

Legionella Found in 17% of NYC Water Samples Outside Cooling Towers

Image
Legionella Found in 17% of NYC Water Samples Outside Cooling Towers

Washington – September 09, 2026 -- Independent testing commissioned by the Alliance to Prevent Legionnaires' Disease (APLD) found Legionella bacteria in 17 percent of 109 water samples collected from sinks, showers, hose bibs and other fixtures across the Upper East Side outbreak zone, results the group says expose gaps in New York City's current prevention strategy.

Testing detected live, culturable Legionella pneumophila serogroup 1 across all three sampled zip codes

The independent consultant collected samples in mid-July across zip codes 10128, 10028 and 10075, the area the City identified as the outbreak zone. Legionella was found in 19 buildings, including 10 exterior hose bibs, seven sinks, one shower and a decorative fountain. Positive samples showed Legionella concentrations ranging from less than 1 to 390 CFU/mL, with Legionella pneumophila serogroup 1 confirmed in all three zip codes.

Pulnovo's PADN Device Cuts Heart Failure Risk 51% in Trial

Shanghai – September 09, 2026 -- Pulnovo Medical's pulmonary artery denervation (PADN) system reduced the risk of clinical worsening by 51% in patients with pulmonary hypertension linked to left heart disease, according to results from the PADN-HF-PH trial presented at the European Society of Cardiology (ESC) 2026 Congress and published simultaneously in The New England Journal of Medicine (NEJM).

Trial of 264 patients shows 51% risk reduction over two-year follow-up

The multicenter, randomized controlled trial, led by academician Yaling Han of the General Hospital of Northern Theater Command, enrolled 264 patients with pulmonary hypertension associated with left heart disease (PH-LHD). Over a median follow-up of 338 days, the estimated two-year incidence of clinical worsening was 25.7% in the PADN-plus-GDMT group versus 51.5% in the guideline-directed medical therapy (GDMT)-alone group (hazard ratio 0.49; 95% CI, 0.30 to 0.82; p=0.006).

Rodeo Dental Names Detrick CEO, Napolitano CFO in Leadership Overhaul

Image
Rodeo Dental Names Detrick CEO, Napolitano CFO in Leadership Overhaul

Irving, Texas – September 09, 2026 -- Rodeo Dental & Orthodontics has appointed Lorri Detrick as Chief Executive Officer and Andrew Napolitano as Chief Financial Officer, restructuring its top leadership as the multi-location dental provider enters its next growth phase.

Co-founder Zarrabi steps back to Executive Chairman role

Dr. Saam Zarrabi, Rodeo's Co-Founder and outgoing CEO, will transition to Executive Chairman, retaining involvement in the company's vision, culture, doctor relationships, patient experience, innovation, and long-term expansion strategy. Zarrabi said the leadership shift was designed to protect the company's mission of expanding access to high-end dental care while adding executives capable of scaling the organization.

Gan & Lee Licenses Obesity Drug Bofanglutida to Menarini for €726M

Beijing/Florence – September 09, 2026 -- Gan & Lee Pharmaceuticals (603087.SH) has signed an exclusive license agreement with Italy's Menarini Group worth up to €726 million, excluding royalties, to develop and commercialize the obesity drug bofanglutida across 39 European markets.

Gan & Lee secures €62 million upfront with milestones reaching €664 million

Under the deal, Gan & Lee will receive an initial payment of €62 million, milestone payments totaling up to €664 million, and double-digit royalties on net sales within the licensed territory. Menarini will handle regulatory filings and commercialization in the 27 European Union member states, the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkan countries.

TraceLink, Omnicell Integrate DSCSA Compliance Into Pharmacy Workflows

Image
TraceLink, Omnicell Integrate DSCSA Compliance Into Pharmacy Workflows

Boston – September 08, 2026 -- TraceLink has integrated its Drug Supply Chain Security Act (DSCSA) compliance solution with Omnicell, Inc. (Nasdaq: OMCL) pharmacy inventory management systems, embedding serialized product verification and traceability directly into hospital medication receiving workflows.

Integration eliminates separate compliance tools during medication receiving

Hospital and health system pharmacies must currently verify, document, and incorporate medication shipments into inventory while resolving compliance exceptions through manual processes that run alongside operational systems. The new integration allows pharmacy teams to verify serialized products, access traceability data, resolve verification exceptions, and complete compliance reporting within Omnicell's central pharmacy inventory management workflows as medications are received.

EpiVax Launches AI-Enhanced ISPRI Platform for Biologics Risk

Image
EpiVax Launches AI-Enhanced ISPRI Platform for Biologics Risk

Providence, R.I. – September 08, 2026 -- EpiVax, Inc. has launched artificial intelligence-driven upgrades to its proprietary ISPRI platform, adding a new JanusMatrix 2.1 model, a tolerance-adjusted immunogenicity score, and an enhanced anti-drug antibody (ADA) prediction model for biotherapeutic developers.

JanusMatrix 2.1 applies AI to weight cross-conservation of human epitopes using expression and prevalence data.
The update is designed to produce more precise characterization of therapeutic epitopes and their tolerance profiles, building on EpiVax's existing EpiMatrix and JanusMatrix algorithms that assess T-cell epitope content and human cross-conservation.